| Drug General Information |
| Drug ID |
D0M9LJ
|
| Former ID |
DNC009063
|
| Drug Name |
N-(4-aminobiphenyl-3-yl)nicotinamide
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C18H15N3O
|
| Canonical SMILES |
C1=CC=C(C=C1)C2=CC(=C(C=C2)N)NC(=O)C3=CN=CC=C3
|
| InChI |
1S/C18H15N3O/c19-16-9-8-14(13-5-2-1-3-6-13)11-17(16)21-18(22)15-7-4-10-20-12-15/h1-12H,19H2,(H,21,22)
|
| InChIKey |
RAJXTGVDLBIWMD-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Histone deacetylase 2 |
Target Info |
Inhibitor |
[1]
|
|---|
| Histone deacetylase 1 |
Target Info |
Inhibitor |
[1]
|
| Histone deacetylase |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
Cell cycle
|
|
Notch signaling pathway
|
|
Thyroid hormone signaling pathway
|
|
Huntington's disease
|
|
Alcoholism
|
|
Epstein-Barr virus infection
|
|
Pathways in cancer
|
|
Transcriptional misregulation in cancer
|
|
Viral carcinogenesis
|
|
Chronic myeloid leukemiahsa04110:Cell cycle
|
|
Amphetamine addiction
|
|
MicroRNAs in cancer
|
|
Chronic myeloid leukemia
|
|
NetPath Pathway
|
TCR Signaling PathwayNetPath_11:TCR Signaling Pathway
|
|
PANTHER Pathway
|
Wnt signaling pathwayP00057:Wnt signaling pathway
|
|
p53 pathway
|
|
Pathway Interaction Database
|
Regulation of nuclear SMAD2/3 signaling
|
|
Signaling events mediated by HDAC Class I
|
|
Regulation of Telomerase
|
|
Glucocorticoid receptor regulatory network
|
|
Direct p53 effectors
|
|
Hedgehog signaling events mediated by Gli proteins
|
|
Regulation of nuclear beta catenin signaling and target gene transcriptionsmad2_3nuclearpathway:Regulation of nuclear SMAD2/3 signaling
|
|
Notch signaling pathway
|
|
E2F transcription factor network
|
|
Presenilin action in Notch and Wnt signaling
|
|
Sumoylation by RanBP2 regulates transcriptional repression
|
|
Regulation of Androgen receptor activity
|
|
IL3-mediated signaling events
|
|
Validated nuclear estrogen receptor alpha network
|
|
Retinoic acid receptors-mediated signaling
|
|
Regulation of nuclear beta catenin signaling and target gene transcription
|
|
Validated targets of C-MYC transcriptional repression
|
|
Regulation of retinoblastoma protein
|
|
Notch-mediated HES/HEY network
|
|
Reactome
|
p75NTR negatively regulates cell cycle via SC1
|
|
NOTCH1 Intracellular Domain Regulates Transcription
|
|
Constitutive Signaling by NOTCH1 PEST Domain Mutants
|
|
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
|
|
HDACs deacetylate histones
|
|
NoRC negatively regulates rRNA expression
|
|
RNA Polymerase I Transcription Initiation
|
|
Factors involved in megakaryocyte development and platelet productionR-HSA-1538133:G0 and Early G1
|
|
Formation of the beta-catenin:TCF transactivating complex
|
|
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
|
|
Deactivation of the beta-catenin transactivating complex
|
|
Factors involved in megakaryocyte development and platelet production
|
|
WikiPathways
|
Notch Signaling Pathway
|
|
Notch Signaling Pathway
|
|
Neural Crest Differentiation
|
|
Signalling by NGF
|
|
RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
|
|
Factors involved in megakaryocyte development and platelet production
|
|
Cell CycleWP706:SIDS Susceptibility Pathways
|
|
TGF beta Signaling Pathway
|
|
IL-6 signaling pathway
|
|
Apoptosis-related network due to altered Notch3 in ovarian cancer
|
|
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
|
|
Retinoblastoma (RB) in Cancer
|
|
TWEAK Signaling Pathway
|
|
Integrated Breast Cancer Pathway
|
|
Mitotic G1-G1/S phases
|
|
Cell Cycle
|
|
Androgen receptor signaling pathway
|
| References |
| REF 1 | Bioorg Med Chem Lett. 2008 Dec 1;18(23):6104-9. Epub 2008 Oct 14.SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2). |
|---|
